Related Experiment Videos
Potential catalysts in therapeutics
1Division of Gastroenterology-Hepatology, University of Iowa, Iowa City, IA.
Abstract:
After years of expecting new advances in immunosuppression, we have not seen a newly developed drug in the past decade. Recent efforts have been centered on minimizing the known side effects of steroids and CNI. It is unlikely that a new CNI will be developed; however, extended-release tacrolimus is available. Most clinical research trials are designed to determine when and how to withdraw steroids or CNI, either substituting mTOR inhibitors or withdrawing an agent completely. As with CNI, there is little evidence that new mTOR inhibitors are in the “publicly viewable” pharmaceutical pipeline. New antibodies that block costimulatory pathways currently have been approved or are being studied in both kidney and liver transplantation (Fig. 14). Most studies are initially performed with other diseases requiring immune modulation such as RA or psoriasis psoriasis. Other blocking antibodies are being studied in kidney transplantation. It is unlikely that these newer agents will be generally available in the next 2 to 3 years. It seems likely that they may find specialized use in specific populations of patients (HCC or HCV infection) for whom the risk of side effects is adequately balanced by the beneficial effects of immunosuppression and prevention of infection or cancer progression.
Insights
New immunosuppression drugs are scarce, with focus on reducing side effects from steroids and calcineurin inhibitors (CNI). Emerging antibody therapies show promise for specific transplant patients, but widespread availability is years away.
Area of Science:
- Immunology
- Transplantation Medicine
- Pharmacology
Background:
- Significant advancements in immunosuppressive drug development have been limited over the last decade.
- Current research focuses on mitigating side effects associated with corticosteroids and calcineurin inhibitors (CNI).
Purpose of the Study:
- To review the current landscape of immunosuppression in transplantation.
- To explore emerging therapeutic strategies, including novel antibodies targeting costimulatory pathways.
Main Methods:
- Analysis of the current pharmaceutical pipeline for immunosuppressive agents.
- Review of clinical trial designs focusing on steroid or CNI withdrawal and the use of mTOR inhibitors.
- Examination of the development and investigation of new antibody therapies in transplantation.
Main Results:
- No new CNI drugs are anticipated, though extended-release tacrolimus is available.
- Clinical trials are primarily investigating the withdrawal or substitution of existing immunosuppressants like steroids and CNI with mTOR inhibitors.
- New costimulatory pathway-blocking antibodies are approved or under study for kidney and liver transplantation, with initial research in other immune-mediated diseases.
- These novel antibodies are unlikely to be widely available within 2-3 years.
Conclusions:
- The development of novel immunosuppressive drugs remains slow, with a focus on optimizing existing therapies.
- Emerging antibody therapies targeting costimulatory pathways represent a promising, albeit specialized, future direction in transplantation.
- These newer agents may offer benefits for specific patient populations, such as those with hepatocellular carcinoma (HCC) or hepatitis C virus (HCV) infection, where risk-benefit profiles are favorable.
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Principles of Drug Action
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drug Discovery: Overview